Complement System
Complement System(补体系统)
The complement system helps or “complements” the ability of antibodies and phagocytic cells to clear pathogens from an organism. It is part of the immune system called the innate immune system that is not adaptable and does not change over the course of an individual's lifetime. The complement system consists of a number of small proteins found in the blood, in general synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is massive amplification of the response and activation of the cell-killing membrane attack complex. Over 30 proteins and protein fragments make up the complement system. Three biochemical pathways activate the complement system: the classical complement pathway, the alternative complement pathway, and the lectin pathway.
Complement System 相关产品(57)
- GC72391AvdoralimabCAS: 2226393-85-5纯度: >95.00%
Avdoralimab(IPH 5401)是一种全人IgGκ单克隆抗体,靶向补体C5a受体1(C5aR1),阻止其与C5a结合。
- GC72473CrovalimabCAS: 1917321-26-6纯度: >98.00%
Crovalimab(SKY59;RO7112689)是一种新型的人源化C5抗体,具有pH依赖性,在pH 7.4和5.8时的KD分别为15.2 nM和16.8μM。
- GC73106Cemdisiran sodium纯度: >96.00%
Cemdisiran sodium是一种N-乙酰半乳糖胺(GalNAc)偶联的siRNA,用于通过抑制肝脏产生补体5(C5)蛋白来研究补体介导的疾病。
- GC74552GefurulimabCAS: 2456407-94-4纯度: >97.00%
Gefurulimab(ALXN-1720)是一种来源于人的针对补体C5和白蛋白的双特异性抗体,可结合C5并阻断其激活。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC72354 | Lampalizumab | 1278466-20-8 | >99.00% | |
Lampalizumab (RG 7417)是一种人源化单克隆抗体,靶向补体因子D的替代补体途径。 | ||||
| GC72391 | Avdoralimab | 2226393-85-5 | >95.00% | |
Avdoralimab(IPH 5401)是一种全人IgGκ单克隆抗体,靶向补体C5a受体1(C5aR1),阻止其与C5a结合。 | ||||
| GC72473 | Crovalimab | 1917321-26-6 | >98.00% | |
Crovalimab(SKY59;RO7112689)是一种新型的人源化C5抗体,具有pH依赖性,在pH 7.4和5.8时的KD分别为15.2 nM和16.8μM。 | ||||
| GC73106 | Cemdisiran sodium | - | >96.00% | |
Cemdisiran sodium是一种N-乙酰半乳糖胺(GalNAc)偶联的siRNA,用于通过抑制肝脏产生补体5(C5)蛋白来研究补体介导的疾病。 | ||||
| GC73413 | ARC186 sodium | - | >94.00% | |
ARC186 sodium是一种未偶联的40KDa PEG适体,其序列与0 Avacincaptad pegol ARC1905钠相同。 | ||||
| GC74045 | Zoracopan | 2243483-63-6 | >99.00% | |
Zoracopan是一种选择性补体因子D(CFD)抑制剂。 | ||||
| GC74354 | Pegcetacoplan acetate | - | >98.00% | |
Pegcetacoplan acetate是一种聚乙二醇化的补体C3抑制剂肽。 | ||||
| GC74552 | Gefurulimab | 2456407-94-4 | >97.00% | |
Gefurulimab(ALXN-1720)是一种来源于人的针对补体C5和白蛋白的双特异性抗体,可结合C5并阻断其激活。 | ||||
| GC74590 | Pozelimab | 2096328-94-6 | >99.00% | |
Pozelimab(REGN3918)是一种全人IgG4抗C5单克隆抗体。 | ||||
